RT Journal Article
SR Electronic
T1 The role of vasopressin in congestive heart failure
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP S19
OP S23
VO 73
IS 9 suppl 3
A1 Phillip Hall
A1 Steven R. Goldsmith
YR 2006
UL http://www.ccjm.org/content/73/9_suppl_3/S19.abstract
AB Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF). Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems. The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF. Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF. Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.